![Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive](/skin/ecms291/images/notimg.gif)
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive
Illustrative photo
Boehringer Ingelheim
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from ba......